Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis

References

• Amgen Inc. Aranesp^® (darbepoetin alfa) package insert. Thousand Oaks, CA: Amgen Inc.; 2011.
   Google Scholar
• Amgen Inc. Aranesp^® (darbepoetin alfa) package insert. Breda, The Netherlands: Amgen Inc.; 2011.
   Google Scholar
• European public assessment reports for authorised medicinal products for human use [Internet]. Available from: www.emea.europa.eu/htms/human/epar/a.htm
   Google Scholar
• Janssen Products LP. PROCRIT® (epoetin alfa) prescribing information. Horsham, PA: Janssen Products LP; 2011.
   Google Scholar
• F. Hoffman-La Roche. NeoRecormon^® (epoetin beta) summary of product characteristics. Welwyn Garden City, UK: Roche Products Limited; 2010.
   Google Scholar
• Roche Products Pty Limited. NeoRecormon^® (epoetin beta) product information. Dee Why, Australia: Roche Product Pty Limited; 2011.
   Google Scholar
• Österborg A, Boogaerts MA, Cimino R, . Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma—a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996;87:2675–2682.
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, . Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–2874.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, . Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211–1220.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Adriansson M, San Miguel J, . Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394–403.
   PubMed Web of Science ®Google Scholar
• Barbara JA. The rationale for pathogen-inactivation treatment of blood components. Int J Hematol 2004;80:311–316.
   PubMed Web of Science ®Google Scholar
• Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med 2007;131:708–718.
   PubMed Web of Science ®Google Scholar
• Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest 2004;126:249–258.
   PubMed Web of Science ®Google Scholar
• EMEA. electronic Medicines Compendium (eMC) [Internet]. Available from: http://emc.medicines.org.uk
   Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, . Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914–924.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, . Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708–714.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Vansteenkiste J, Kotasek D, . Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23:6941–6948.
   PubMed Web of Science ®Google Scholar
• Amgen Inc. in collaboration with Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Background information for the Oncologic Drugs Advisory Comittee (ODAC) meeting, 13 March 2008 [Internet]. Available from: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-00-FDA-index.htm
   Google Scholar
• Katodritou E, Verrou E, Hadjiaggelidou C, . Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 2008;83:697–701.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Anderson K, Dammacco F, . ESAs not the culprit: more studies required. Am J Hematol 2008;83:880; author reply 880–881.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, . Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373: 1532–1542.
   PubMed Web of Science ®Google Scholar
• Glaspy J, Crawford J, Vansteenkiste J, . Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301–315.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Hemmelgarn B, Reiman T, . Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62–E71.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Messinger D, Battistel V, . Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446–4453.
   PubMed Web of Science ®Google Scholar
• Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172–179.
   PubMed Web of Science ®Google Scholar
• Cabanillas M, Kantarjian H, Thomas D, . Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma. Cancer 2012;118:848–855.
   PubMed Web of Science ®Google Scholar
• Österborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 2005;129:206–209.
   PubMed Web of Science ®Google Scholar
• Pangalis GA, Poziopoulos C, Angelopoulou MK, . Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br J Haematol 1995;89:627–629.
   PubMed Web of Science ®Google Scholar
• Engert A, Josting A, Haverkamp H, . Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010;28:2239–2245.
   PubMed Web of Science ®Google Scholar
• Delarue R, Haioun C, Coiffier B, . Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: the LNH03-6B study. J Clin Oncol 2011;29(Suppl.): Abstract 9048.
   Google Scholar
• Hedenus M, Hansen S, Taylor K, . Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79–86.
   PubMed Web of Science ®Google Scholar
• Rose E, Rai K, Revicki D, . Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994;84(Suppl. 1): Abstract 2091.
   Google Scholar
• Cazzola M, Beguin Y, Kloczko J, . Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386–393.
   PubMed Web of Science ®Google Scholar
• Österborg A, Brandberg Y, Molostova V, . Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486–2494.
   PubMed Web of Science ®Google Scholar
• Aapro M, Coiffier B, Dunst J, . Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br J Cancer 2006;95:1467–1473.
   PubMed Web of Science ®Google Scholar